Beta Blocker Toxicity
Conditions
Brief summary
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Detailed description
Clinical study evaluating selective or nonselective beta blockers use and if there is fracture risk in patients with primary osteoporosis
Interventions
DRUGnonselective beta blocker
nonselective beta blocker
DRUGcardio-selective beta blocker group
cardio-selective beta blocker group
alendronate sodium
Sponsors
Sherief Abd-Elsalam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Male & female osteoporotic patient aged ≥ 50 years * Hypertensive & normotensive patients * BMD T-score ≥ 2.5 or more SD below peak bone mass
Exclusion criteria
* Patients on drugs that may improve osteoporosis disease state such as: * Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins. Patients on drugs that may worsen osteoporosis disease state such as: • Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with fracture in each group | 1 year | the exact number of patients with fracture in each group |
Countries
Egypt
Contacts
Primary ContactSherief Abd-Elsalam, ass. prof.
Outcome results
None listed